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OUTCOMES OF AUDITORY BRAINSTEM IMPLANTATION IN ADULTS WITH 
POSTLINGUAL DEAFNESS: A SYSTEMATIC REVIEW     
    by 
 
      Jillian Friedman 
 
Advisor: Carol A. Silverman, Ph.D., M.P.H. 
Objective: The purpose of this investigation is to conduct a systematic review of the long-term 
speech-recognition outcomes of ABIs in postlingually deafened adults, and to compare outcomes 
of ABIs in adults with NF2/tumors to adults without NF2.  
Methods: A comprehensive search utilizing various peer reviewed databases via the City 
University of New York (CUNY) Graduate Center Library was conducted to identify relevant 
studies investigating speech-recognition outcomes in ABI patients with postlingual deafness, 
both with and without tumors. Inclusion criteria included studies that involved at least one adult 
ABI patient (with or without NF2) with postlingual deafness, who was seen for follow-up 
auditory performance testing at one-year post-activation or later. 
Results: Thirteen articles met inclusion criteria for this systematic review. The studies utilized 
various materials for speech-recognition assessment to evaluate speech-recognition performance. 
Because of the great diversity among the materials used for speech-recognition assessment, the 
measures have been categorized as either closed-set (CS) or open-set (OS). Total overall sample 
size across the 13 included studies was 170. Of the 170 participants, 91 (54%) were adults with 
postlingual deafness; 76 participants (84%) were adults with NF2, and 15 participants (16%) 




Discussion: Significant long-term improvement and overall good closed-set and fair open-set 
speech performance with use of the ABI only was found for the participants with NF2. 
Participants with NF2 also performed better on closed-set and open-set tests when using the ABI 
in conjunction with LR. Improved open-set performance was also observed in the ABI+LR 
condition for individuals without NF2.  
Conclusions: Results of ABI are unpredictable and a wide range in speech-recognition 
performance was observed. ABIs generally provide good support in the communication skills of 
deafened patients, especially in combination with lip reading. Standardization of speech-
recognition performance testing and clinical case reporting will be crucial to make more 
definitive statements about the factors that influence these outcomes, as the indications for ABI 
implantation in both postlingually and prelingually deafened individuals continues to expand.  
Key words: auditory brainstem implant, ABI, adult, postlingual, neurofibromatosis type 2, NF2, 
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 According to Otto and Winter (2013), more than 2,000 people have received auditory 
brainstem implants (ABIs) worldwide (as cited by American Academy of Audiology, 2014). The 
ABI, previously known as the cochlear nuclei implant, first was introduced in 1979 in Los 
Angeles, California, by Drs. William House and William Hitselberger. The implant was created 
initially for individuals with neurofibromatosis type 2 (NF2), a genetic disease marked by the 
predisposition to develop a variety of tumors of the central and peripheral nervous systems. One 
of the defining symptoms of NF2 is the growth of bilateral vestibular schwannomas, also 
commonly referred to as acoustic neuromas. The growth or removal of these tumors typically 
results in damage to the auditory nerve and subsequent deafness. As a result of the damage to the 
auditory nerve, these patients generally are not candidates for cochlear implantation. 
Rehabilitation of some auditory sensation, however, can be achieved by an ABI (Møller, 2006).   
 The U.S. Food and Drug Administration (FDA) approved the ABI in the year 2000 for 
treatment of deafness in persons who are at least 12 years of age and who lost their ability to hear 
because of NF2.  Currently in the United States, the ABI is still only FDA approved for adults 
with NF2. Clinical trials are being conducted to expand candidacy to those with auditory nerve 
damage from etiologies other than NF2. Outside of the United States, ABIs have been performed 
on, and are available to, young children and adults with auditory nerve damage not resulting 
from NF2. These individuals anatomically are not candidates for cochlear implantation and may 
have lost their hearing because of congenital or acquired conditions, such as ossification or 





Development of ABI 
 The ABI, like the cochlear implant, comprises an external microphone, speech processor, 
transcutaneous transmitter coil, and receiver stimulator. Instead of an electrode array, an 
electrode paddle is placed within the brainstem on the surface of the cochlear nucleus. The 
external microphone picks up sound that then is converted into an electrical signal by the speech 
processor. The speech processor delivers the coded signal to the transmitter coil, which is 
attached to the internal receiver stimulator by a removable magnet, magnetic resonance imaging 
(MRI) compatible magnet, or specific adhesive. From the internal receiver stimulator, the signals 
are sent to the electrode paddle, which directly stimulates the cochlear nucleus of the auditory 
brainstem (Sennaroglu & Ziyal, 2012). The requirement for repeated, lifelong MRI scanning 
means that the impact and risk of complications of procedures to remove and reinsert a magnet is 
greater in individuals with NF2 than in individuals without NF2. The results of recent studies 
suggest that MRI scanning without magnet removal is safe and well tolerated in NF2 patients 
with ABIs. Image quality is not significantly impaired and no risk to the patient or the implanted 
device exists with an ABI having a magnet (Walton et al., 2014). 
The first ABI was a simple ball-type electrode that was implanted in an NF2 patient 
following removal of an acoustic neuroma by Drs. House and Hitselberger in 1979 at the House 
Ear Institute. The implant, used with a modified, body-worn hearing aid, provided useful 
auditory sensation (Eisenberg et al., 1987). The first 25 patients who received ABIs before 1992 
received single-channel devices. In 1992, the single-channel implant was replaced by the 
multichannel implant. A two-electrode, and subsequent three-electrode, mesh type array was 





 Cochlear Limited, in conjunction with Huntington Medical Research Institute, developed 
two different electrode prototypes, one used in the United States and one used in Europe. The 
American device had eight electrodes whereas the European model comprised a flat, silicone 
plate-electrode carrier with 21 plate electrodes. Both electrode arrays were used with the 
Cochlear Nucleus 22 ABI external speech processors (Laszig et al., 1999). In 1999, the Nucleus 
24 ABI speech processor was introduced, which utilizes different stimulation strategies than the 
Nucleus 22 ABI, provides the possibility of performing intraoperative electrical monitoring of 
the neural interface, neural response telemetry (NRT), and contains a removable magnet (Colletti 
et al., 2005).  
 Although the Cochlear Nucleus 24 ABI system is the only FDA approved device in the 
U.S., additional ABI systems from various manufacturers (e.g., Med-El, Neurolec, and 
Advanced Bionics) have been discussed in the literature. Med-El developed their ABI electrode 
from the Med-El Combi 40+ cochlear implant. The receiver stimulator has an array with 12 
platinum electrodes, which are embedded in a silicone carrier.  The Med-El ABI also includes a 
non-removable magnet that is MRI compatible (Colletti, 2006).   
The Neurolec Digisonic ABI has 15 electrodes on an electrode carrier, and does not have 
a removable magnet (Sanna, Di Lella, Guida, & Merkus, 2012). The Advanced Bionics Clarion 
ABI, based on the Clarion 1.2 cochlear implant, consists of a Silastic electrode array with 16 
electrodes. Dacron mesh is also attached to the posterior surface of the array. The Clarion is a 
magnet-free system and has a special headset to hold the headpiece in place (Lenarz et al., 2001).  
Indications for ABI 
 The prevailing approach to surgical treatment of auditory nerve damage is to attempt 




cochlear implant cannot be effectively placed in the cochlea or it fails to furnish benefit (Merkus 
et al., 2014). The indications for an ABI can broadly be divided into three groups: postlingually 
deafened patients with tumors, postlingually deafened patients without tumors (nontumor), and 
prelingually deafened patients. The patients with tumors are those individuals with NF2 and 
bilateral vestibular schwannomas. The patients without tumors represent postlingually deafened 
patients with severe cochlear ossification, surgical problems preventing normal cochlear 
implantation, or cochlear/internal auditory canal fractures (Sennaroglu & Ziyal, 2012). The 
prelingually deafened patients are those children with total hearing loss due to severe cochlear 
anomalies, cochlear nerve disorders or failed cochlear implantation. These conditions can 
include developmental or acquired cochlear nerve deficiency (CND), cochlear aplasia, post-
meningitis cochlear ossification, or cochlear malformation. 
Initially, the majority of ABI users with NF2 reported increased sound awareness that 
facilitated lip-reading ability; very few, however, had open-set speech perception (Schwartz et 
al., 2008; Sanna et al., 2012). In contrast with the findings that ABIs provide limited benefit in 
patients with NF2, Colletti and colleagues (2005; 2006; 2009) observed that ABIs yield high 
levels of open-set speech recognition without visual cues in patients without tumors. The results 
of several studies indicate that ABI patients without tumors demonstrate improved audiometric 
outcomes when compared with the findings of those with NF2 (Colletti & Shannon, 2005; 
Colletti, 2006; Colletti et al., 2009; Grayeli et al., 2003). Some of these individuals are able to 
achieve better than 50% recognition of sentences presented in quiet and are able to converse on 
the telephone. Such findings suggest that the ABI device with electrode placement in the lateral 
recess of the IV ventricle can yield good speech recognition. The limited speech understanding 




of recent studies, however, show that the ABI can provide high levels of speech recognition in 
NF2 patients that are comparable to, and in part better than, the speech-recognition findings in 
patients without NF2 (Behr et al., 2007; Matthies et al., 2014). The excellent speech recognition 
results found in ABI patients with NF2 suggest that the cause of improved speech understanding 
is not related to NF2 alone. Prior to surgery, some patients with NF2 have normal-hearing 
sensitivity and speech recognition in the ear with a tumor, even with a large tumor, indicating 
that the presence of the tumor itself does not necessarily cause an auditory deficit. The loss of 
hearing and speech recognition in most NF2 patients may result from tumor interference with the 
blood supply to the cochlea, VIIIth nerve, and/or cochlear nucleus. Additionally, physical 
compression by the tumor of the nerve and brainstem might impair neural excitability. The 
recent improvement in speech-recognition performance in patients with NF2 may result from 
differences in patient etiology, surgical technique and damage to the brainstem before and during 
tumor removal, electrode placement, device design, signal/speech processing, or other factors 
(Behr et al., 2014).  
The purpose of this investigation is to conduct a systematic review of the long-term 
speech-recognition outcomes of ABIs in postlingually deafened adults, and to compare outcomes 











 A systematic review was performed targeting studies investigating speech outcomes in 
ABI patients with postlingual deafness, both with and without tumors. A literature search was 
conducted using the following peer reviewed databases to identify the relevant studies published 
in English: Academic Search Complete, Scopus, PubMed, Google Scholar, and CINAHL Plus 
with Full Text. Various combinations of the following key terms were included: “auditory 
brainstem implant”, “ABI”, “adult”, “neurofibromatosis type 2”, “NF2”, “vestibular 
schwannoma”, “acoustic neuroma”, “nontumor”, “cochlear ossification”, “meningitis”, “cochlear 
trauma”, “altered cochlear patency”, “speech recognition”, “speech understanding”.  The terms 
“child” and “pediatric” were at times included in the search strings using Boolean operator 
“NOT” to limit retrieval of irrelevant studies.  
Inclusion of published studies in this systematic review was guided by PRISMA 
(Preferred Reporting Items for Systematic reviews and Meta-analyses), as described by Moher 
and colleagues (2009). The PRISMA Statement consists of a 27-item checklist and a four-phase 
flow diagram (Fig. 1), the aim of which is to help authors improve the reporting of systematic 
reviews and meta-analyses.  
Search inclusion and exclusion criteria were designed to capture as many patients as 
possible for review, and no papers were excluded on the basis of quality. Inclusion criteria 
included studies that involved at least one adult ABI patient (with or without NF2) with 
postlingual deafness, who was seen for follow-up auditory performance testing at one-year post-
activation or later. Studies were excluded if speech-recognition results were obtained only at 




search exclusion criteria included articles in languages other than English, unavailable full-length 
articles, or unpublished studies.  
It should be noted that in some cases, different publications by investigators at a single 
center are duplicative in that the same patients may be represented in the different publications. 
This occasionally is the case in articles based on two or more centers in which the results from at 
least one center were published in another article. Some series report on all their ABI patients as 
one group with various indications, instead of presenting an NF2/tumor group and nontumor 
group separately. The participants in several applicable articles also contain both prelingual 
children and postlingual adults; in such instances, however, only the studies with analysis of the   
postlingual group that is independent from the analysis of the prelingual group have been have 
been included in this review.  
Articles that met inclusion criteria were assessed for year of publication, sample size, 
follow-up time, speech-recognition outcome measures, and conclusions. The following patient 
characteristics were extracted when available: age at implantation, sex, tumor size in those with 
NF2, etiology in those without NF2, duration of deafness prior to implantation, surgical 
technique for ABI implantation, type of ABI device implanted, number of active electrodes, and 











Figure 1 shows a PRISMA flowchart for the literature search and retrieval process for the 





















Figure 1. PRISMA flowchart of the literature search and retrieval process. The PRISMA Group (2009).  
Records identified through database 
searching  






























 Additional records identified 
through other sources  
(n = 4) 
Records after duplicates removed  
(n = 84) 
Records screened  
(n = 34) 
Full-text articles assessed 
for eligibility  
(n = 34) 
Full-text articles 
excluded, with reasons  
(n = 21) 
 3 review 
articles 
 6 did not 
include speech 
outcomes 









Studies included in 





Perusal of the abstracts of these articles retrieved by the search indicated that 84 articles were 
irrelevant or were duplicates, resulting in 30 articles for this review. Examination of the 
reference lists of articles identified by the search revealed another 4 articles relevant to the study 
topic. Following full article review, it was determined that 13 articles met inclusion criteria for 
this systematic review.   
Table 1 shows the study design, number and participant group (NF2 or Non-NF2), 
material used for speech-recognition assessment, and testing conditions.  
Table 1 
Studies Meeting Inclusion Criteria 




Behr et al. (2006) aRCR/C 14 (NF2)  bOS-N (Freiburg 
numbers) 
 cOS-S (Innsbruck 
sentences) 
dABI, eABI+LR 
Choi et al. (2011) 
RCR/C 
3 (Non-NF2)  fCS-S 
 OS-S (Daily Sentences in 
Korean) 
ABI, ABI+LR 
Colletti et al. (2004) 
RCR/C 
4 (Non-NF2)  gCS-W 
 hOS-W (iSTT) 
 OS-S  
ABI  
 
OS-W: 70dB SPL 
Goffi-Gomez et al. (2012) 
RCR/C 





 OS-S  
kMLV at 70dB SPL 
Grayeli et al. (2006)**; 
Grayeli et al. (2008)** 
RCR/C; 
lRCS 
7 (Non-NF2)  OS-W (French Fournier 
List-disyllabic words) 
 OS-S  
ABI, mLR, ABI+LR 
Kalamarides et al. (2001) RCR/C 3 (NF2)  OS-W (French Fournier 
List-disyllabic words) 
 OS-S 
ABI, LR, ABI+LR 
Kanowitz et al. (2004) RCR/C 11 (NF2)  CS-W (nMTS-S & oMTS-
W; pNU-CHIPS) 









 OS-S (qCID) 
Lenarz et al. (2001) rPCS 8 (NF2)  CS-V 
 sCS-C 
 OS-N (Freiburg 
numbers) 
 OS-W (STT) 
CS-V, CS-C, OS-W: 
ABI, ABI+LR (MLV) 
 
OS-N: ABI (recorded) 
Maini et al. (2009) RCR/C 10 (NF2)  OS-S (tBKB, uCUNY) ABI, LR, ABI+LR 
Matthies et al. (2014) 
PCS 
15 (NF2)  CS-W (vMTP) 
 OS-S(wHSM) 
CS-W: ABI, ABI+LR 
OS-S: ABI 
Sanna et al. (2012) 
RCR/C 
13 (NF2)  OS-W (xNU-6 in Italian) 
 OS-S (yCP, CID) 
ABI (MLV) 
70 dB SPL (15 dB 
SNR) 
Wu et al. (2000) 
RCR/C 
3 (NF2)  CS-V 
 CS-C 
 zCS-N 
 CS-W (colors)  
 OS-W (disyllabic words) 
 OS-S  
CS-V, CS-C, CS-N, 
CS-W: ABI 
OS-W, OS-S: ABI, 
ABI+LR 
aRCR/C = retrospective chart review/cases; bOS-N = open-set numbers; cOS-S = open-set sentences; dABI = 
auditory brainstem implant; eABI+LR = auditory brainstem implant + lip-reading; fCS-S = closed-set sentences; 
gCS-W = closed-set words; hOS-W = open-set words; iSTT = Speech-tracking test; jCS-V = closed-set vowels; 
kMLV = monitored live voice; lRCS = retrospective cohort study; mLR = lip-reading; nMTS-S = Monosyllable, 
Spondee, Trochee Stress Test; oMTS-W = Monosyllable, Spondee, Trochee Word Test; pNU-CHIPS = Northwestern 
University Children’s Perception of Speech; qCID = Central Institute for the Deaf Everyday Sentences Test; rPCS = 
prospective cohort study; sCS-C = closed-set consonants; tBKB = Bench-Kowal-Bamford Sentence test; uCUNY = 
City University of New York Sentence Test; vMTP = Monotrochee-polysyllabic Word Test; wHSM = Hochmair-
Schulz-Moser sentence test; xNU-6 = Northwestern University Phonetically Balanced Word List; yCP = common 
phrases (e.g., “How are you feeling?”); zCS-N = closed-set numbers 
Note** = 3 participants from the Grayeli et al. (2006) article were included in the Grayeli et al. (2008) article and 
have only been counted once 
 
Inspection of Table 1 reveals that 77% (10 of 13) of the studies were retrospective chart 
review/case reports (RCR/C), 15% (2 out of 13) were prospective cohort studies (PCS), and 8% 
(1 of 13) were retrospective cohort studies (RCS). Of the 13 studies included for review, 
participant data were extracted from: 8 studies (61%) on patients with NF2, 4 studies (31%) on 




The studies utilized various materials for speech-recognition assessment to evaluate 
speech-recognition performance. Because of the great diversity among the materials used for 
speech-recognition assessment, the measures also have been categorized as either closed-set (CS) 
or open-set (OS) (see Table 1). Closed-set measures were further classified based on the type of 
closed-set test used, which includes, vowels (CS-V), consonants (CS-C), numbers (CS-N), words 
(CS-W), and sentences (CS-S). Similarly, open-set measures were further classified as numbers 
(OS-N), words (OS-N), and sentences (OS-S). The specific speech measures, testing conditions 
(ABI, LR, ABI+LR), presentation mode (recorded, MLV), and presentation level that were 
reported in each study can also be found in Table 1. As shown, the majority of studies did not 
report specific presentation mode (69%), 15% of studies (2 of 13) reported using MLV, 1 study 
(8%) reported sole use of recorded speech materials, and 1 study (8%) indicated use of both 
recorded materials and monitored-live voice.  
Subject Characteristics  
 Total overall sample size across the 13 included studies was 170. Of the 170 participants, 
91 (54%) were adults with postlingual deafness; follow-up data on these participants were 
available based on test sessions at 12 months or later 
Group with NF2 


























Behr et al. (2007)            
 1 (2) 22 M  5 cRS Med-El Combi 40+   eY 
 2 (3) 27 F  4 RS Med-El Combi 40+   Y 
 3 (4) 46 F  20 RS Med-El Combi 40+   Y 
 4 (9) 18 F  3 RS Med-El Combi 40+   Y 
 5 (11) 17 M  0.5 RS Med-El Combi 40+   Y 
 6 (12) 19 M  2 RS Med-El Combi 40+   Y 
 7 (14) 46 F  2 RS Med-El Combi 40+   Y 
 8 (16) 30 M  13 RS Med-El Combi 40+   Y 
 9 (19) 30 M  1 RS Med-El Combi 40+   Y 
 Mean (SD) 28.3 
(11.1) 
  5.6 (6.6)   7.7 (?) 12 & 24  
Goffi-Gomez et al. 
(2012)  
          
 1 (1) 28 M 3.5 cm  dTL Cochlear N24 3 48  
 2 (2) 26 M 4.0 cm  TL Cochlear N24 8 36  
 3 (3) 27 F Intracanal 
tumor 
 TL Cochlear N24 7 36  
 4 (4) 23 M 2.0 cm  TL Cochlear N24 14 36  
 Range 23-28  2.0-4.0 cm    3-14 36-48  
Kalamarides et al. 
(2001) 
          
 1 (1) 49 F 2.5 cm 0.5 TL Cochlear N22 14 24 Y 
 2 (2) 55 F 2.0 cm 15 TL Cochlear N22 9 24 Y 
 3 (3)  17 F 2.4 cm 0.5 TL Cochlear N22 5 24 Y 
 Range 17-55  2.0-2.4 cm 0.5-15   5-14 24  
Kanowitz et al. 
(2004) 
          
 1 (1) 15  2.0 cm  TL Cochlear N22  36 fN 
 2 (2) 55  1.2 cm  TL Cochlear N22  60 Y 
 3 (3) 32  2.5 cm  TL Cochlear N22  78 Y 
 4 (5) 19  2.0 cm  TL Cochlear N22  18 N 
 5 (7) 30  1.5 cm  TL Cochlear N22  18 N 























 7 (11) 33  2.0 cm  TL Cochlear N22  60 Y 
 8 (12) 18  4.0 cm  TL Cochlear N22  20 Y 
 9 (14) 22  2.0 cm  RS Cochlear N24  14 Y 
 10 (15) 43  9.0 cm  TL Cochlear N24  16 Y 
 11 (16) 32  3.5 cm  TL Cochlear N24  13 Y 
 Mean (SD) 29.6 
(11.7) 
 3.2 cm 
(2.4) 
    32.5 
(22.8) 
 
Lenarz et al. (2001)           
 1 (1)     TL Cochlear N22  12  
 2 (2)     RS Cochlear N22  12  
 3 (3)     RS Cochlear N22  12  
 4 (4)     RS Cochlear N22  12  
 5 (5)     RS Cochlear N22  12  
 6 (6)     RS Cochlear N22  12  
 7 (7)     RS Cochlear N22  12  
 8 (8)     RS Cochlear N22  12  
 Mean (SD)          
Maini et al. (2009)           
 1 (1) 25     Cochlear N22  132  
 2 (2) 44     Cochlear N22  144  
 3 (3) 35     Cochlear N22  24  
 4 (4) 30     Cochlear N24  96  
 5 (5) 23     Cochlear N24  72  
 6 (6) 46     Cochlear N24  48  
 7 (7) 25     Cochlear N24  48  
 8 (8) 17     Cochlear N24  12  
 9 (9) 46     Cochlear N24  48  
 10 (10) 33     Cochlear N24  24  
 Mean (SD) 32.4 
(10.3) 
   TL (9); RS 
(1) 
  64.8 
(45.7) 
Y (7); N 
(2); 
gD(1) 
Matthies et al. (2014)           
 1 (1) 36 M 32.4 cm3 0.17 RS Med-El Pulsar 9 12 & 24 Y 
 2 (2) 22 M 20.9 cm3 1 RS Med-El Pulsar 8 12 & 24 Y 
 3 (4) 46 F 11.8 cm3 0.17 RS Med-El Pulsar 8 12 & 24 Y 























 5 (7) 27 F 20.4 cm3 0.17 RS Med-El Pulsar 9 12 & 24 Y 
 6 (8) 19 F 11.8 cm3 1 RS Med-El Pulsar 8 12 & 24 Y 
 7 (10) 51 F 5.8 cm3 4 RS Med-El Pulsar 6 12 & 24 Y 
 8 (11) 66 M 1.4 cm3 0.17 RS Med-El Pulsar 9 12 & 24 Y 
 9 (12) 43 F 3.4 cm3 0.5 RS Med-El Pulsar 7 12 & 24 Y 
 10 (13) 42 M 8.1 cm3 0 RS Med-El Pulsar 5 12 & 24 Y 
 11 (14) 31 M 4.3 cm3 8 RS Med-El Pulsar 5 12 & 24 Y 
 12 (15) 42 M 44.1 cm3 0 RS Med-El Pulsar 5 12 & 24 Y 
 13 (16) 33 M 7.9 cm3 13 RS Med-El Pulsar 5 12 & 24 Y 
 14 (17) 27 M 15.4 cm3 0.25 RS Med-El Pulsar 7 12 & 24 Y 
 15 (18) 25 F 1.2 cm3 2 RS Med-El Pulsar 8 12 & 24 Y 
 Mean (SD) 39.7 
(14.4) 
 13.8 cm3 
(12.0) 
2.3 (3.7)   7.4 (2.0)   
Sanna et al. (2012)           
 1 (1) 34 F 3.0 cm  TL Cochlear N24 21 53 Y 
 2 (2) 43 F 2.5 cm  TL Cochlear N24 19 44 Y 
 3 (3) 33 F 4.4 cm  TL Cochlear N24 18 40 Y 
 4 (4) 35 M 0.5 cm  TL Cochlear N24 13 46 Y 
 5 (5) 41 M 4.0 cm  TL Cochlear N24 19 33 Y 
 6 (6) 39 M 8.0 cm  TL Cochlear N24 10 30 Y 
 7 (7) 69 F 1.5 cm  TL Cochlear N24 13 23 Y 
 8 (8) 26 F 2.0 cm  TL Cochlear N24 12 18 Y 
 9 (11) 20 F 3.0 cm  TL Cochlear N24 6 12 Y 
 10 (12a) 52 M 5.0 cm  TL Cochlear N24 0 24 N 
 11 (15) 39 M 3.0 cm  TL Cochlear N24 0 12 N 
 12 (16) 18 M 2.0 cm  TL Cochlear N24 21 16 Y 
 13 (23) 26 M 3.0 cm  TL Neurolec MXM 9 36 Y 
 Mean (SD) 36.5 
(13.6) 
 3.2 cm 
(1.9) 
   12.4 (7.3) 29.8 
(13.5) 
 
Wu et al. (2000)           
 1 (1) 30 F  4 TL Cochlear N22 21 36 Y 
 2 (2) 4 F 2.0 cm  TL Cochlear N22 4 30 Y 
 3 (3) 27 M  7 TL Cochlear N22 7 24 Y 
 Range 27-44   4-7   4-21 24-36  
aDoD = duration of deafness; bABI = auditory brainstem implant; cRS = retrosigmoid (also referred to as suboccipital); dTL = translabyrinthine; eY = yes; fN = 




The number in parentheses in the participant column of Table 2 represents the subject 
number in the study so the reader can refer back to the study; participants were numbered 
sequentially in this review. Studies ranged in sample size from 3 participants to 15 participants. 
The following patient characteristics were extracted when available: age at implantation, sex, 
tumor size, duration of deafness prior to implantation, surgical technique, type of ABI device 
implanted, number of active electrodes, and ABI usage. 
In studies that mentioned age individually, ages ranged from 15 to 69 years old. The ratio 
of males (32%, 24 of 76) to females (30%, 23 of 76) was essentially equal across the studies; 
gender, however, was not identified in all of the patients. Tumor size ranged from 0.5 
centimeters to 9.0 centimeters. One study reported tumor size in cubic centimeters (Matthies et 
al., 2014) making comparison with other studies difficult. The period of time between age at 
deafness and age at implantation, also referred to as duration of deafness, ranged from as little as 
no time at all, to as long as 20 years. The translabyrinthine surgical approach (57% or 43 of 76) 
was more commonly performed for tumor removal and ABI implantation than the retrosigmoid 
(suboccipital) surgical approach (43% or 33 of 76). The Cochlear Nucleus 24 (34% or 26 of 76) 
and Cochlear Nucleus 22 (33%, 25 of 76) ABI devices were implanted in the majority of the 
participants (67%). The remaining participants were implanted with the Med-El Pulsar (20% or 
15 of 76), Med-El Combi 40+ (12%, 9 of 76), and Neurolec MXM (13%, 1 of 76) ABI devices. 
Individual data regarding the number of active electrodes in the ABI device were available for 38 
of 76 participants (50%). Based on these participants, the number of active electrodes ranged 
from 3 to 21. In one study, two participants did not have any active electrodes, as they do not 
regularly use their ABI due to normal hearing on the contralateral side (Sanna et al., 2012). 




64 of the 76 participants. Fifty-six participants (73%) use their ABI device regularly, 7 (9%) 
participants do not use it at all, and 1 (1%) participant had passed away two years after 
implantation and was regularly using the device.  
Group without NF2 (Non-NF2) 
Table 3 shows the participant characteristics in the group without NF2. As shown in 
Table 3, 15 of the 91 subjects (16%) were adults without NF2. The number or letters in 
parentheses in the participant column represents the subject number/identifier in the study so the 







Subject Characteristics (Group without NF2) 
aDoD = duration of deafness; bABI = auditory brainstem implant; cRS = retrosigmoid (also referred to as suboccipital); dTL = translabyrinthine; eY = yes; fN = 


















Choi et al. (2011)           
 1 (9) 49  Cochlear Ossification 3 cRS Med-El Pulsar 12 14 eY 
 2 (10) 51  Cochlear Ossification 3.5 RS Med-El Pulsar 0 12 fN 
 3 (11) 56 M Cochlear Ossification 0.5 RS Med-El Pulsar 12 15 Y 
 Range 49-56   0.5-3   0-12 12-15  
Colletti et al. (2004)           
 1 (AS) 35 M Head Trauma 18 RS Cochlear N24 8 12 Y 
 2 (DM) 32 M Head Trauma 13 RS Cochlear N24 16 14 Y 
 3 (CL) 24 F Head Trauma 18 RS Cochlear N24 13 12 Y 
 4 (DGM) 32 M Head Trauma 5 RS Cochlear N24 10 12 Y 
 Range 24-35   5-18   8-16 12-14  
Goffi-Gomez et al. (2012)           
 1 (5) 21 M Cochlear Ossification   Cochlear N24 10 60  
Grayeli et al. (2006);  
Grayeli et al. (2008) 
          
 1 (SEG) 48 M Cochlear Ossification 3 dTL Cochlear N22 11 100 Y 
 2 (FABM)  37 F Cochlear Ossification 2 RS Cochlear N22 14 43 Y 
 3 (KAB)  42 M Cochlear Ossification 3 RS Cochlear N22 13 31 Y 
 4 (PRY) 69  
VS + contralateral 
cholesteatoma 
0 TL  14 35 Y 
 5 (FABG)  71  
VS + contralateral severe 
SNHL 
0 TL  7 26 N 
 6 (DAC)  51  
VS + contralateral sudden 
SNHL 
0 TL  7 21 N 
 7 (CEC)  41  
Mondini-type 
malformation 
33 RS  9 55 Y 




Three patients in the group without NF2 appeared to have been evaluated in two studies 
(Grayeli et al., 2006; Grayeli et al., 2008). These patients underwent surgery at the same institute 
and had equivalent characteristics, such as age at implantation, gender, etiology, duration of 
deafness, surgical approach, implanted device, number of active electrodes, and follow-up time 
(one year and beyond). Therefore, data from both studies were combined for analysis and the 
participants have been counted only once to represent a more accurate sample size. Patient 
characteristics that were extracted whenever available are shown in Table 3 as follows: age at 
implantation, gender, etiology of the hearing loss, duration of deafness prior to implantation, 
surgical technique, type of ABI device, number of active electrodes, and patient usage of the 
ABI.  
As can be seen from Table 3, participant age ranged from 21 to 71 years (mean = 44, SD 
14.6). Gender was specified for 9 of the 15 participants. Male patients were more highly 
represented than females in this sample (47% or 7 of 15 were males and 13% or 2 of 15 were 
females). The etiology of the hearing loss was cochlear ossification in 7 patients (47%), head 
trauma in 4 patients (27%), unilateral vestibular schwannoma with hearing loss in the 
contralateral ear in 3 patients (20%), and Mondini-type malformation in 1 patient (6%). The 
duration of deafness ranged from 0 to 33 years (mean = 7.3, SD 9.7). In contrast with the group 
with NF2, the retrosigmoid surgical approach (employed in 67% or 10 of 15) was more common 
for ABI implantation than the translabyrinthine approach (employed in 27% or 4 of 15). The 
surgical approach was unspecified for one subject (Goffi-Gomez et al., 2012).  Type of ABI 
device implanted was specified for 11 of the 15 participants. Based on these participants, the 
Cochlear Nucleus 24 device was implanted in the majority (33%, 5 of 15), followed by both the 




number of participants (20%, 3 of 15). The number of active electrodes was reported for all 
participants in this group; one participant, however, had no active electrodes; that participant was 
unable to use the ABI device because of nonauditory stimulation such as tingling sensations in 
the arm and throat (Choi, Song, Jeon, Lee, & Chang, 2011). Choi and colleagues suggest that the 
nonauditory stimulation observed in this subject may have been caused by the substitution of 
neural components of the brainstem or cerebral cortex associated with auditory function with 
those related to other functions because of the long period of auditory deprivation. Follow-up 
data ranged from 12 months to 8 years. Follow-up data obtained after 1 year were available in 11 
participants (73%), and follow-up data obtained after 2 years were available in 7 participants 
(47%).  
As shown in Table 3, ABI use was specified for 14 of the 15 participants: 11 participants 
(73%) use their ABI device regularly and 3 participants (20%) do not use it all.  
As previously mentioned, reasons for nonusage of the ABI was the presence of normal or 
residual hearing in the contralateral ear. Other reasons for nonusage or discontinued use included 
occurrence of nonauditory stimulation, absence of auditory sensation, electrode migration, or 
other health-related issues. 
Speech Performance 
Closed-Set Speech Recognition Findings (Group with NF2) 
 Table 4 shows the closed-set (CS) speech results for each participant in the group with 
NF2. Results were extracted from the initial testing session following ABI activation, and from 
the follow-up testing session at 12 months or later. In some of the included  
studies, initial test session speech-recognition results were unreported (Goffi-Gomez et al., 2012; 








Closed-Set Speech Recognition Findings (Group with NF2) 
 
  Initial Test Session Follow-up Test Session (12+ Months) 
Study Participant CS-Va CS-Cb CS-Wc CS-V CS-C CS-Nd CS-W CS-Se 
Goffi-Gomez et 
al. (2012) 
         
 1    100%   100% 100% 
 2    46%   58% 0% 
 3    40%   75% 0% 
 4    86%   100% 100% 
 Range    40-100%   58-100% 0-100% 
Kanowitz et al. 
(2004) 
         
 1-8 (N22f) 
Mean (SD) 













 9-11 (N24j) 
Mean (SD) 





45.3% (11)  
 
Lenarz et al. 
(2001) 
         












   



























   








  Initial Test Session Follow-up Test Session (12+ Months) 





















   












   












   












   
















   
Matthies et al. 
(2014) 
         
 1 (1)   100% (ABI) 
100% 
(ABI+LR) 









 2 (2)   95.8% (ABI) 
100% 
(ABI+LR) 















  Initial Test Session Follow-up Test Session (12+ Months) 
Study Participant CS-Va CS-Cb CS-Wc CS-V CS-C CS-Nd CS-W CS-Se 
 3 (4)   87.5 (ABI) 
100% 
(ABI+LR) 









 4 (6)   16.7% (ABI) 
100% 
(ABI+LR) 









 5 (7)   75% (ABI) 
100% 
(ABI+LR) 









 6 (8)   54.2% (ABI) 
95.8% 
(ABI+LR) 









 7 (10)   41.7% (ABI)  
100% 
(ABI+LR) 












  Initial Test Session Follow-up Test Session (12+ Months) 




 8 (11)   100% (ABI) 
100% 
(ABI+LR) 









 9 (12)   87.5% (ABI) 
100% 
(ABI+LR) 









 10 (13)   75% (ABI) 
100% 
(ABI+LR) 









 11 (14)   83.3% (ABI) 
100% 
(ABI+LR) 


















  Initial Test Session Follow-up Test Session (12+ Months) 









 13 (16)   66.7% (ABI) 
100% 
(ABI+LR) 









 14 (17)   79.2% (ABI) 
100% (ABI) 









 15 (18)   66.7% (ABI) 
100% 
(ABI+LR) 



























  Initial Test Session Follow-up Test Session (12+ Months) 





Wu et al. (2000)          
 1    93% 94% 100% 100%  
 2    0% 0% 30% 50%  
 3    73% 71% 60% 70%  
 Range    0-93% 0-94% 30-
100% 
50-100%  
aCS-V = closed-set vowels; bCS-C = closed-set consonants; cCS-W = closed-set words; dCS-N = closed-set numbers; eCS-S = closed-set sentences; fN22 = 
Cochlear Nucleus 22; gMTS-W = Monosyllable, Spondee, Trochee Word Test; hMTS-S = Monosyllable, Spondee, Trochee Stress Test; iNU-CHIPS = 
Northwestern University Children’s Perception of Speech; jN24= Cochlear Nucleus 24; kn.d. = no data; lABI = auditory brainstem implant; mABI+LR = auditory 




The closed-set vowel (CS-V) tests generally consisted of a predetermined list of long 
(e.g., BAAT, GAAT) and short (e.g., BAT, GAT) monosyllable vowels. Initial CS-V results for 
both the auditory-only condition (referred to as ABI), and auditory-plus-visual/lip-reading 
condition (referred to as ABI +LR) were reported in one study (Lenarz et al., 2001). In the 
Lenarz study, participants were tested in the ABI only condition and ABI+LR condition. The 
average initial CS-V score was 52% (SD 23.6) in the ABI condition, and 87.4% (SD 9.5) in the 
ABI+LR condition. The average follow-up CS-V score was 51.4% (SD 23.6) in the ABI 
condition, and 92.5% (SD 5.2) in the ABI+LR condition. The results from this study reveal that 
CS-V scores are improved with the use of the ABI, in conjunction with LR. However, the results 
at the one-year follow-up session were essentially unchanged when compared to the initial test 
session for the ABI and ABI+LR conditions. In two other studies, very variable CS-V scores 
were obtained at the follow-up session, ranging from 0 to 93% in the ABI condition (Wu et al., 
2000) and from 40-100% in an unspecified condition (Goffi-Gomez et al.,2012). 
The closed-set consonant test generally consisted of a predetermined list of meaningless 
consonant words (e.g., ABA, AGA). Closed-set consonant (CS-C) results for both the ABI and 
ABI+LR condition were also reported in the Lenarz et al. (2001) study. The average initial CS-C 
score was 27.5% (SD 3.5) in the ABI condition, and 72.5% (SD 14.5) in the ABI+LR condition. 
The average follow-up CS-C score was 36% (SD 11.8) in the ABI condition, and 75.8% (SD 
14.4) in the ABI+LR condition. The results from this study indicate that CS-C scores are also 
improved with use of both the ABI and LR; however, the follow-up results were essentially 
unchanged from the initial session for both the ABI and ABI+LR conditions (Lenarz et al., 
2001). Wu et al. (2000) reported considerable intersubject variability in CS-C scores obtained at 




A wide variety of closed-set word (CS-W) tests were used among the included studies. 
Kanowitz and colleagues (2004) obtained both initial and follow-up speech-recognition results in 
the ABI condition using the Monosyllable, Spondee, Trochee Word Test (MTS-W), 
Monosyllable, Spondee, Trochee Stress Test (MTS-S), and the Northwestern University 
Children’s Perception of Speech Test (NU-CHIPS). Follow-up data were reported from the most 
recent follow-up testing session (mean follow-up time = 32.5 months, SD 22.8) for each 
individual participant (see Table 2). They reported mean scores for two groups: those implanted 
with the Cochlear Nucleus 22 (N22) ABI and those implanted with the Cochlear Nucleus 24 
(N24) ABI (but initial test scores were not reported for this group). As can be seen from Table 4, 
the mean gain in test performance from initial test to follow-up for the group with the N22 ABI 
was 8.7% for the MTS-W, 9.9% for the MTS-S, and no gain for the NU-CHIPS. Follow-up 
mean scores for the N24 group were 43.2% (SD 18.8%) on the MTS-W test, 80.1% (SD 14.6%) 
on the MTS-S test, and 45.3% (SD 11%) on the NU-CHIPS test. When comparing the results of 
the N22 group with the N24 group, the data indicate a trend toward higher MTS-W, MTS-S and 
NU-CHIPS scores in participants with the N24 ABI than with the N22 ABI (Kanowitz, Shapiro, 
Golfinos, Cohen, & Roland, 2004).  
Matthies and colleagues (2014) also reported initial and follow-up speech results at 12 
and 24 months in the ABI and ABI+LR conditions using the Monotrochee-Polysyllabic Word 
Test (MTP). The mean average gain in test performance from initial test to follow-up was 14.4% 
in the ABI condition at 12 months, and 15.1% in the ABI condition at 24 months (see Table 4). 
Follow-up results show improvement in scores in the ABI condition at 12 months (88%, SD 
16.6) and 24 months (88.7%, SD 12.6); whereas, results in the ABI+LR condition were 




were present at the initial test. Wu and colleagues (2000) obtained considerable intersubject 
variability in the follow-up CS-W (based on names of colors) scores in the ABI condition, as the 
scores ranged from 50 to 100%. Goffi-Gomez and colleagues (2012) also observed similar large 
intersubject variability on the CS-W at follow-up as the scores ranged from 58 to 100%; the 
testing condition and specific CS-W measure used, however, were unspecified. Based on closed-
set numbers (CS-N), Wu et al. obtained large intersubject variability in performance as the scores 
in the ABI condition that ranged from 30-100%.  Based on closed-set sentences (CS-S), Goffi-
Gomez and colleagues obtained very large intersubject variability in performance as the scores 
ranged from 0 to 100%; but the testing condition and specific CS-S measure used were 
unspecified. 
Closed-Set Speech Recognition Findings (Group without NF2) 
 Table 5 shows the three studies that reported closed-set (CS) speech-recognition results 
for the group without NF2. 
Table 5  
Closed-Set Speech Recognition Findings (Group without NF2) 
 
aCAP = Categories of Auditory Performance (index consisting of 8 categories relating to auditory perception); bCS-
V = closed-set vowels; cCS-W = closed-set words; dCS-S = closed-set sentences; eABI+LR = auditory brainstem 
implant + lip-reading; fNAS = Non-auditory stimulation (tingling sensations) 
 
  Initial test session Follow-up test session (12+ months) 
Study Participant aCAP bCS-V cCS-W dCS-S CAP 
Choi et al. (2011)       
 1 (9) 1   60% (eABI + LR) 3.5 
 2 (10) 1   fNAS 1 
 3 (11) 2    5 
 Range 1-2   60% 1-5 
Colletti et al. (2004)       
 1 (AS)   92%   
 2 (DM)   100%   
 3 (CL)   90%   
 4 (DGM)   42%   
 Range   42-100%   
Goffi-Gomez et al. (2012)       




  In one study (Choi et al., 2011), individual Categories of Auditory Performance (CAP) 
scores were reported that were obtained at the initial test session and at the follow-up test 
session. The CAP, an index consisting of 8 categories relating to auditory perception, measures 
supraliminal performance in a more realistic way. The CAP scores ranged from 1 to 2 at the 
initial test session, and from 1 to 5 at the 1-year follow-up test session. In this study, follow-up 
data on CS-S for one participant who scored 60% in the ABI+LR condition at the initial session 
were presented, although the specific CS-S measure used was not reported. Goffi-Gomez and 
colleagues (2012) also reported CS-S scores, as well as CS-V and CS-W scores, for one 
participant; although condition and specific measures were unspecified. The participant obtained 
20% on CS-V, 33% on CS-W, and 10% on CS-S, at the 5-year follow-up test session. Colletti 
and colleagues (2004) also reported CS-W data obtained from four participants that ranged from 
42% to 100% in the ABI condition using an unspecified speech-recognition test.  
Open-Set Speech Recognition Findings (Group with NF2) 
 Table 6 shows the open-set speech-recognition results for each participant in the group 
with NF2. The results were extracted from the initial testing session following ABI activation, 
and from the follow-up testing session at 12 months or later. Initial open-set test results, as well 







Table 6  
Open-Set Speech Recognition Findings (Group with NF2) 
 
 Initial test Session Follow-up test session (12+ Months) 
Study Participant  aOS-N bOS-W cOS-S OS-N OS-W OS-S 
Behr et al. (2007)        
 dABI only users  
Mean (SD) 
   12 mos: 69.5% (40) 
24 mos: 51.7% (en.d.) 
 12 mos: 48.4% 
(37.4) 
24 mos: 42.7% 
(n.d.) 
 ABI only users (fn)     12 mos: 5 
24 mos: 9 
 12 mos: 6 
24 mos: 8 
 gABI+LR users 
Mean (SD)  
   12 mos: 87.5% (8.6) 
24 mos: 81.3% (n.d.) 
 12 mos: 79.3% 
(17.2) 
24 mos: 67.5% 
(n.d.) 
 ABI +LR users (n)    12 mos: 5 
24 mos: 5 
 12 mos: 5 
24 mos: 9 
 hBG 
Mean (SD)  
   12 mos: 84.3% (13.6) 
24 mos: 78.5% (n.d.) 
 12 mos: 81.3% 
(13.6)  
24 mos: 71.1% 
(n.d.) 
 BG (n)    12 mos: 7 
24 mos: 11 
 12 mos: 7 
24 mos: 12 
Goffi-Gomez et al. 
(2012) 
       
 1      20% 
 2      0% 
 3      0% 
 4      60% 
 Range      0-60% 
Kalamarides et al. 
(2001) 
       


















 Initial test Session Follow-up test session (12+ Months) 
Study Participant  aOS-N bOS-W cOS-S OS-N OS-W OS-S 














Kanowitz et al. 
(2004) 
       
 1-8 (jN22) 
Mean (SD) 
     0% 
 9-11 (kN24) 
Mean (SD) 
     0% 
Lenarz et al. (2001)        
 1 20% lSTT: 10 
words/min 
 35% STT: 21 
words/min 
 
 2 0% STT: 17.2 
words/min 
 0% STT: 46.6 
words/min 
 
 3 0% STT: 5.8 
words/min 
 80% STT: 12.8 
words/min 
 
 4 20% STT: 36 words/min  55% STT: 54.4 
words/min 
 
 5 0% STT: 7.6 
words/min 
 15% STT: 9 words/min  
 6 0% STT: 15.6 
words/min 
 0% STT: 16.4 
words/min 
 
 7 20% STT: 14.2 
words/min 
 20% STT: 26 
words/min 
 
 8 0% STT: 30.2 
words/min 
 20% STT: 25.2 
words/min 
 




 28% (28) STT: 26.4 
words/min (16) 
 
Maini et al. (2009)        









 Initial test Session Follow-up test session (12+ Months) 
Study Participant  aOS-N bOS-W cOS-S OS-N OS-W OS-S 
 4-10 (N24)      ~20% (LR) 
~10% (ABI) 
~62% (ABI+LR) 
Matthies et al. 
(2014) 
       
 1 (1)   64.2%    12 mos: 86.8%  
24 mos: 86.8%  
 2 (2)   12.3%   12 mos: 60.4%  
24 mos: 85%  
 3 (4)   2.8%   12 mos: 81.1%  
24 mos: 81.1% 
 4 (6)   0%   12 mos: 0%  
24 mos: n.d.  
 5 (7)   12.2%   12 mos: 28.3%  
24 mos: 28.3%  
 6 (8)   0%   12 mos: 10.4%  
24 mos: 10%  
 7 (10)   0%   12 mos: 0%  
24 mos: 0%  
 8 (11)   99.1%   12 mos: 97.2%  
24 mos: 99%  
 9 (12)   39.6%   12 mos: 12.3%  
24 mos: 24%  
 10 (13)   3.8%   12 mos: 14.2%  
24 mos: 14%  
 11 (14)   0%    12 mos: 16%  
24 mos: 40% 
 12 (15)   0%   12 mos: 5.7% 
24 mos: 16%  
 13 (16)   0%   12 mos: 0%  
24 mos: 6%  
 14 (17)   22.6%   12 mos: 38.7% 
24 mos: 39%  
 15 (18)   0%   12 mos: 36.8%  
24 mos: 51%  
 Mean (SD)   17% 
(29) 








 Initial test Session Follow-up test session (12+ Months) 
Study Participant  aOS-N bOS-W cOS-S OS-N OS-W OS-S 
24 mos: 41.4% 
(32.4) 
Sanna et al. (2012)        
 1 (1)     90% mCP: 100% 
nCID: 100% 
 2 (2)     70% CP: 72% 
CID: 80% 
 3 (3)     80% CP: 70% 
CID: 75% 
 4 (4)     0% CP: 0% 
CID: 0% 
 5 (5)     0% CP: 0% 
CID: 0% 
 6 (6)     30% CP: 15% 
CID: 20% 
 7 (7)     10% CP: 0% 
CID: 0% 
 8 (8)     30% CP: 35% 
CID: 30% 
 9 (11)     80% CP: 0% 
CID: 0% 
 10 (12a)     n.d. n.d. 
 11 (15)     0% CP: 0% 
CID: 0% 
 12 (16)     60% CP: 65% 
CID: 70% 
 13 (23)     0% CP: 0% 
CID: 0% 
 Mean (SD)     38% (36) CP: 17.2% (33.8) 
CID: 17.2% (34.3) 
Wu et al. (2000)        




 2     0% (ABI) 









 Initial test Session Follow-up test session (12+ Months) 
Study Participant  aOS-N bOS-W cOS-S OS-N OS-W OS-S 








aOS-N = open-set numbers; bOS-W = open-set words; cOS-S = open-set sentences; dABI = auditory brainstem implant; en.d. = no data; fn = number of subjects; 
gABI+LR = auditory brainstem implant + lip-reading; hBG = both groups (combined group of ABI-only performers and those using ABI+LR); iLR = lip-reading; 
jN22 = Cochlear Nucleus 22; kN24 = Cochlear Nucleus 24; lSTT = Speech-tracking test; mCP = common phrases (e.g., “How are you feeling?”); nCID = Central 




 Lenarz and colleagues (2001) reported an average gain of 20% on the Freiburg numbers 
test (OS-N), in the ABI condition from the initial test to follow-up. In congruence with the 
Lenarz study (2001), Behr and colleagues (2006) also reported follow-up OS-N findings using 
the Freiburg numbers test for ABI only users, ABI + LR users, and the combined ABI only users 
plus ABI+LR users. Inspection of Table 6 reveals that the average OS-N scores reported at 12 
months appear to be higher than those reported at 24 months among all three groups. 
Furthermore, greatest gain in performance was observed in the ABI+LR group, as compared 
with the ABI only group and the combined group, at both 12 and 24 months. 
Lenarz and colleagues (2001) also obtained open-set word (OS-W) scores at the initial 
and follow-up test sessions in the ABI+LR condition, using the speech-tracking test (STT). In 
the STT, a story is read to the patient in monitored live voice (MLV) and the patient’s task is to 
correctly repeat the sentences or words. The number of correct words per minute in a 5-minute 
session is determined. The sentences present different levels of difficulty. The score for 
individuals with normal-hearing sensitivity is between 70 and 80 words per minute (Colletti et 
al., 2006). Lenarz and colleagues reported an average gain of 9.4 words per minute from the 
initial test to follow-up. The OS-W scores obtained at the follow-up test session were reported in 
3 additional studies--two studies used disyllabic word test measures (Kalamarides et al., 2001; 
Wu et al., 2000), and one study used the Northwestern University Phonetically Balanced (NU-6) 
word list (Sanna, Di Lella, Guida, & Merkus, 2012). Sanna (2012) found the average OS-W 
score was 38% (SD 36) for the ABI condition. In the Kalamarides et al. study, three participants 
were tested in the lip-reading only condition (LR), ABI only condition, and ABI+LR condition. 
Scores ranged from approximately 5% to 55% for the LR condition, 0 to 30% for the ABI 




OS-W scores of three participants in the ABI condition, and ABI+LR condition. Scores ranges 
from 0 to 60% for the ABI condition, and from 0 to 90% for the ABI+LR condition. The results 
from both Kalamarides et al. and Wu et al. reveal that OS-W scores are improved with the use of 
the ABI, in conjunction with LR.  
Matthies et al. (2014) reported open-set sentence (OS-S) results obtained at the initial test 
session, at the 12-month follow-up, and at the 24-month follow-up, in the ABI condition. The 
average gain from initial to follow-up was 15.5% at 12 months and 24.4% at 24 months. The OS-
S scores obtained at the follow-up test session were reported in seven additional studies. Behr 
and colleagues (2006) reported follow-up OS-S findings using the Innsbruck sentence test for 
ABI only users, ABI + LR users, and the combined ABI only users plus ABI+LR users. Similar 
to the OS-N results reported by Behr, the average OS-S scores collected at 12 months are higher 
than the average OS-S scores at 24 months in all three groups. Average OS-S scores appear to be 
highest in the combined group, as compared to the ABI only group and ABI+LR group. 
Interestingly, the sample size was larger in each group at 24 months than at 12 months. 
Kalamarides et al. (2001) and Wu et al. (2000) obtained OS-S scores in the same 
conditions as employed for OS-W scores (sentence tests were unspecified). In agreement with 
their OS-W findings, the OS-S scores are also improved with use of both the ABI and LR. 
Furthermore, Maini, Cohen, Hollow, and Briggs (2009) obtained similar OS-S results using the 
Bench-Kowal-Bamford (BKB) Sentence Test and City University of New York (CUNY) 
Sentence Test. Testing was performed in the LR condition, ABI condition, and ABI+LR 
conditions. Average results for each condition were reported for two groups: those implanted 
with the Cochlear N22 ABI and those implanted with the Cochlear N24 ABI. Scores were 




accordance with the findings of Kalamarides et al. and Wu et al. Additionally, Maini et al. (2009) 
observed no significant difference in the mean OS-S score between the N22 and N24 groups. 
Kanowitz and colleagues (2004) also evaluated OS-S scores for the N22 and N24 groups; 
however, none of the patients obtained open-set speech discrimination when tested with the 
Central Institute for the Deaf Everyday Sentences Test (CID). Sanna et al. (2012) also used the 
CID sentence test to evaluate OS-S, as well as the common phrases comprehension test (CP) 
(e.g., “How are you feeling?”). The average follow-up score on both the CP test and CID test 
was 17.2% in the ABI condition. Goffi-Gomez and colleagues (2012) also reported follow-up 
OS-S scores that ranged from 0 to 60%, which again did not indicate the testing condition or 
specific OS-S measure used.  
Open-Set Speech Recognition Findings (Group without NF2) 
 Table 7 shows the open-set speech-recognition results for each participant in the group 
without NF2.  
Table 7 
Open-Set Speech Recognition Findings (Group without NF2) 
 Follow-up test session (12+ months) 
Study Participant aOS-W bOS-S 
Choi et al. (2011)    
 1 (9)   
 2 (10)  cNAS 
 3 (11)  32% (dABI) 
96% (eABI + LR) 
 Range  32% (ABI) 
96% (ABI+LR) 
Colletti et al. (2004)    
 1 (AS) fSTT: 19 words/min 60% 
 2 (DM) STT: 43 words/min 100% 
 3 (CL) STT: 12 words/min 45% 
 4 (DGM) STT: 0 words/min 0% 
 Range 0-43 words/min 0-100% 
Goffi-Gomez et al. (2012)    
 1 (5)  0% 
Grayeli et al. (2006) **; 
Grayeli et al. (2008) ** 
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aOS-W = open-set words; bOS-S = open-set sentences; cNAS = Non-auditory stimulation (tingling sensations); dABI 
= auditory brainstem implant; eABI+LR = auditory brainstem implant + lip-reading; fSTT = Speech-tracking test; 
gLR = lip-reading 
 
As shown in Table 7, none of the investigators reported initial open-set data. In two 
investigations, OS-W scores were reported, and in all of the investigations, OS-S scores were 
reported.  
 Colletti et al. (2004) evaluated OS-W scores using the Speech-Tracking Test (STT) in the 
ABI condition, similar to Lenarz et al. (2001) for their group with NF2. Based on the four 
participants, STT follow-up scores ranged from 0 to 43 words per minute. Grayeli and colleagues 
(2006; 2008) tested seven participants in the LR condition, ABI condition, and ABI+LR 
condition, using disyllabic words. The OS-W follow-up scores ranged from approximately 0% to 
70% for the LR condition, 0 to 50% for the ABI condition, and 20% to 90% for the ABI+LR 




conjunction with LR; these findings are in agreement with those of Kalamarides et al. (2001) and 
Wu et al. (2000) for the group with NF2.  
Improved performance was also observed for the OS-S scores in the ABI+LR condition, 
as compared with the ABI condition or LR condition, as shown in Table 7 (Choi et al., 2011; 
Grayeli et al., 2006; 2008). The remaining investigators who reported follow-up test session OS-
S scores observed very variable performance among the participants. Colletti et al. (2004) 
evaluated OS-S for the four participants in the ABI condition and scores ranged from 0 to 100%.  
Goffi-Gomez and colleagues (2012) also reported OS-S scores for one participant (0%), which 
































The primary purpose of this investigation was to perform a systematic review of the 
existing literature on long-term speech-recognition outcomes of ABIs in postlingually deafened 
adults, and to compare outcomes of ABIs in adults with NF2/tumors to adults without NF2.  
Several investigators indicated significant long-term improvement and overall good 
closed-set speech performance with use of the ABI only, for the participants with NF2 
(Kanowitz et al., 2004; Matthies et al., 2014). In addition, closed-set speech performance was 
further enhanced when auditory and visual modes (ABI+LR) were combined (Lenarz et al., 
2001). As for the group without NF2, closed-set speech-recognition performance was too 
variable to allow overall conclusions to be drawn (Choi et al., 2011; Colletti et al., 2004; Goffi-
Gomez et al., 2012).  
Similarly, significant long-term improvement and overall fair open-set speech 
performance with use of the ABI only was also found in individuals with NF2 (Lenarz et al., 
2001; Matthies et al., 2014). Participants also performed better on open-set tests when using the 
ABI in conjunction with LR (Kalamarides et al., 2001; Maini et al., 2009; Wu et al., 2000). This 
finding also applied to the participants without NF2, as improved open-set performance was 
observed in the ABI+LR condition, when compared with performance in the ABI condition or 
LR condition (Choi et al., 2011; Grayeli et al., 2006; 2008).  
The results of one study indicated higher closed-set speech performance in individuals 
with NF2 who were implanted with the Cochlear Nucleus 24 ABI device, as compared with the 
scores of those implanted with the Cochlear Nucleus 22 ABI device (Kanowitz et al., 2004). In 
contrast with the closed-set findings suggested by Kanowitz, Maini et al. (2009) observed no 




Reported ABI device usage among both the group with NF2 and the group without NF2 
is high, suggesting that participants are receiving subjective benefit, independent of the objective 
scores obtained on speech-recognition tests. A small number of participants became non-users or 
discontinued use of their ABI device because of the presence of normal or residual hearing in the 
contralateral ear, occurrence of nonauditory stimulation, absence of auditory sensation, electrode 
migration, or other health-related issues. 
The considerable degree of intersubject variability in speech-recognition performance 
among both groups may be attributed to patient, surgical, and/or device related factors. The 
results of recent studies suggest that duration of deafness is correlated with ABI performance; in 
other words, better speech-recognition outcomes are associated with shorter rather than longer 
duration of deafness (Colletti et al., 2009; Grayeli et al., 2008). Patients with a short duration of 
deafness (<1 year) generally seemed to have higher speech-recognition scores than those with a 
longer period of deafness in both the NF2 and non-NF2 populations (Choi et al., 2011; Matthies 
et al., 2014). As this was true for some participants included in this review, many studies did not 
provide individual data regarding duration of deafness. Additionally, several participants with 
long durations of deafness performed at very high levels that were comparable, or even better 
than, those with shorter durations of deafness (Colletti et al., 2004; Grayeli et al., 2006; 2008; 
Kalamarides et al., 2001; Wu et al., 2000). Therefore, individuals with longstanding deafness 
should still be considered for ABI implantation as some benefit, whether it be enhanced lip-
reading ability or acquiring open-set speech-recognition ability, is possible.  
Additionally, the results of recent research indicate that tumor size has no influence on 
ABI outcome. In the Matthies et al. (2014) study, the most favorable results were achieved in 




poor to moderate outcomes. Interestingly, the patients with larger tumors and better speech 
recognition outcomes were also the patients with the shortest duration of deafness. Beyond tumor 
size, the presence and growth of the tumor or removal of the tumor can alter the anatomic 
landmarks and adversely affect the auditory pathways, thereby negatively influencing the 
physiological response and overall speech-recognition performance. This explanation may 
account for the findings in some studies of better speech-recognition outcomes among 
individuals without NF2 than in individuals with NF2 (Colletti & Shannon, 2005; Colletti, 2006; 
Colletti et al., 2009; Grayeli et al., 2003).   
An important finding of this systematic review is that the majority of studies on this topic 
reflect low or moderate levels of evidence. None of the studies are randomized clinical trials. 
Also, because of the small sample sizes of many of the included studies, considerable 
intersubject and interstudy variability was seen in terms of duration of deafness of included 
participants, age at implantation, test conditions, test materials and methodology.  
 Future research on long-term speech-recognition outcomes in patients with ABI should 
be based on larger sample sizes with control for various factors including time at which follow-
up testing is performed, duration of deafness, type of ABI device implanted, as well as the 
specific stimulation mode and signal processing strategy of the ABI device. One major point 
raised by this review is the need for a standardized test battery to measure outcomes when 
studying ABI patients with or without NF2. The heterogeneity of speech-recognition materials 












In this systematic review, the existing literature on long-term speech-recognition 
outcomes of ABIs in postlingually deafened adults was reviewed, and the speech-recognition 
outcomes of ABIs in adults with NF2/tumors were compared with those in adults without NF2.  
The findings of the reviewed studies show significant long-term improvement and overall 
good closed-set speech performance and fair open-set speech performance with use of the ABI 
only in individuals with NF2 (Kanowitz et al., 2004; Lenarz et al., 2001; Matthies et al., 2014). 
Participants with NF2 also performed better on closed-set and open-set tests when using the ABI 
in conjunction with LR (Kalamarides et al., 2001; Lenarz et al., 2001; Maini et al., 2009; Wu et 
al., 2000). As for individuals without NF2, improved open-set performance was also observed in 
the ABI+LR condition, when compared with performance in the ABI condition or LR condition 
(Choi et al., 2011; Grayeli et al., 2006; 2008).  
The results of one study indicated higher closed-set speech performance in individuals 
with NF2 who were implanted with the Cochlear Nucleus 24 ABI device, as compared with the 
scores of those implanted with the Cochlear Nucleus 22 ABI device (Kanowitz et al., 2004). In 
contrast with the closed-set findings suggested by Kanowitz, Maini et al. (2009) observed no 
significant difference in the mean open-set scores between the N22 and N24 groups. Therefore, 
no clear conclusion can be drawn at this time, as to whether speech-recognition outcomes are 
significantly better for one device than another. 
Considerable advances have been made since Drs. House and Hitselberger first 
introduced the ABI in 1979. Although the results of ABI are unpredictable and a wide range in 
speech-recognition performance was observed, ABIs generally provide good support in the 




Standardization of speech-recognition performance testing and clinical case reporting will be 
crucial to make more definitive statements about the factors that influence these outcomes, as the 
indications for ABI implantation in both postlingually and prelingually deafened individuals 
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